Irfan Ansari, MD
Ophthalmology · Frankfort, KYNPI 1043207228
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Glaukos Corporation at 44.6% of the total. Reporting peaked in 2020 at $3,520 and has fallen 92.4% since, to $266 in 2025.
Across 140 payments — averaging $48.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Alcon$867
- AbbVie$577
- Johnson & Johnson Surgical Vision, Inc.$401
- Regeneron Healthcare Solutions, Inc.$325
- Genentech USA, Inc.$269
- plus $1K from 21 others
Across 1 payment — averaging $7600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$8K
What the payments were for
- Speaking & faculty fees$3,00044%
- Food & beverage$3,82156%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 4 | $3,052 |
| Alcon | 42 | $867 |
| AbbVie(2 entities) | 16 | $577 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $401 |
| Regeneron Healthcare Solutions, Inc. | 9 | $325 |
| Genentech USA, Inc. | 3 | $269 |
| Sight Sciences, Inc. | 4 | $253 |
| Sun Pharmaceutical Industries Inc. | 5 | $144 |
| Apellis Pharmaceuticals, Inc. | 2 | $144 |
| Aerie Pharmaceuticals, Inc. | 8 | $133 |
| Rayner Intraocular Lenses Limited | 7 | $129 |
| Eyevance Pharmaceuticals LLC | 5 | $77 |
| Novartis | 5 | $70 |
| Harrow Eye, LLC | 3 | $69 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $65 |
| Rxsight Inc | 2 | $49 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| NEW World Medical,inc. | 2 | $31 |
| Steris Corporation | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
| LKC Technologies, Inc. | 1 | $14 |
| Ivantis, Inc | 1 | $12 |
| Integra Lifesciences Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,846 in reported general payments places this provider in the 85th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 260 | $562,422 |
| Eylea HdAflibercept | 30 | $77,505 |
| IlevroNepafenac | 73 | $26,915 |
| XiidraLifitegrast | 15 | $23,732 |
| CombiganBrimonidine Tartrate/Timolol | 86 | $21,197 |
| RestasisCyclosporine | 18 | $11,013 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $9,979 |
| Prednisolone Acetate | 336 | $9,331 |
| RhopressaNetarsudil Mesylate | 21 | $9,035 |
| MoxifloxacinMoxifloxacin Hcl | 251 | $7,636 |
| LumiganBimatoprost | 15 | $6,536 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $6,260 |
| Latanoprost | 546 | $5,284 |
| Brimonidine Tartrate | 132 | $4,986 |
| Fluorometholone | 68 | $4,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $325 | $639,927290 claims |
| AbbVieCombigan, Restasis, Lumigan | $577 | $38,745119 claims |
| NovartisIlevro | $70 | $26,91573 claims |
| Bausch & Lomb Americas Inc.Xiidra | $38 | $23,73215 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $133 | $15,29538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Frankfort
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Ryan SmithLexington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.